Your AI-powered SEBI-registered investment advisor — with research you can trust and insights that grow with you.
Download inXits Free
April 21, 2026
You see a headline like “Wipro announces ₹15,000 crore buyback at ₹250” and it immediately feels like an opportunity. A 23% premium over the current price looks straightforward. Buy shares at ₹202 (as on 20th April, 2026), tender at ₹250, and pocket the difference. But this is exactly where many investors pause. Something feels unclear. […]
August 24, 2026
India’s pharmaceutical industry is known not only for finished medicines but also for the active pharmaceutical ingredients (APIs) that form the foundation of those medicines. The Symbiotec Pharmalab IPO offers investors an opportunity to participate in a pharmaceutical and biotechnology company with a specialised position in steroidal APIs, complex injectables and contract development and manufacturing. […]
March 23, 2026
Many investors notice IPO announcements and feel a mix of curiosity and hesitation. On one hand, IPOs appear as early entry opportunities. On the other, the lack of clarity around business models, risks, and financials often creates confusion. This is especially true in sectors like pharmaceuticals, where terms like “CDMO,” “sterile injectables,” or “regulated markets” […]
inXits is India’s SEBI-registered Investment Advisor, Research Analyst and AMFI registered Mutual Fund Distributor. Manage all your investments, bank accounts and loans in one-place with certified professional backed guidance — 24/7 free support.
No thanks, I’ll manage on my own
